SEC23A and sickle cell disease: Therefore, genetic strategies aimed at increasing SEC23A levels therapeutically for CDAII may be performed exclusively in erythroid cells, limiting the possibility of complications in other cells, as recently shown for other erythroid disorders such as sickle cell disease (65).